Skip to content

Time limited Experiential schema therapy: Naturalistic study for Groups of Outpatients with personality disorders (TENGO)

Time limited Experiential schema therapy: Naturalistic study for Groups of Outpatients with personality disorders (TENGO) - Effect of time limited experiential schematherapy for personality disorders

Status
Unknown
Phases
Phase 2
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON50656
Enrollment
78
Registered
2022-01-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Personality disorders

Interventions

None listed

Sponsors

Parnassia (Den Haag)
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Personality disorder 2. Age at least 18 years 3. Eligibility for group therapy based on a. symptoms of PD are the reason for seeking help, the patient is motivated to follow psychotherapy in a group, and c. the clinical impression of the group therapists. The latter means that the patient is able to attend group meetings, the patient dares to show himself within a group and the patient is able to reflect on the input of other patients.

Exclusion criteria

Exclusion criteria: 1. Acute crisis (suicidality) for which patient needed inpatient treatment, 2. Acute psychotic episode or psychotic disorder, autism spectrum disorder or alcohol or drugs-related disorders as primary diagnosis 3. Limited knowledge of the Dutch language 4. Severe auditory problems that interfere with participation in a group, or severe stuttering. 5. Estimated IQ below 70

Design outcomes

Primary

MeasureTime frame
Severity of general psychiatric symptoms (Brief Symptom Inventory) Severity of symptoms of personality disorders (Personality Inventory for DSM-5* Brief Form (PID-5-BF)

Secondary

MeasureTime frame
Functioning in daily life (World Health Organization Disability Assessment Schedule 2.0, WHODAS-2) Data will be collected at baseline, midway and end of treatment, and 6 and 12 months of follow-up. The following four predictive factors will be explored for treatment success and : signs of autism (AQ-10), rigidity (subdomain BRIEF-A), latent low scorers mode profile and severity of general psychiatric symptoms (Brief Symptom Inventory, BSI) after three months of treatment.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)